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Abstract 44 
45 
Background: Allergic asthma is a chronic inflammatory disease that is characterized by airway 46 
hyper responsiveness (AHR), infiltration of Th2 cells in lungs and high levels of circulating IgE. 47 
Allergen-specific immunotherapy (SIT), in which patients are rendered tolerant by exposure to 48 
steadily increasing doses of the allergen, is the only curative treatment to date. Unfortunately, SIT 49 
is not suitable for treating multi-sensitized patients, and some allergens are too immunogenic to 50 
be used in desensitization protocols. 51 
52 
Objective: To investigate whether, and to understand how, regulatory CD4
+
 T cells (Treg)53 
specific for a third-party “drug” antigen could control allergic immune responses and lung 54 
inflammation. 55 
56 
Methods: Mice were tolerized to ovalbumin (OVA), sensitized to ragweed, and eventually 57 
challenged with aerosols of ragweed alone or ragweed and OVA together. Animals were then 58 
monitored for cardinal features of allergic asthma including AHR and infiltration of Th2 cells in 59 
lungs. In additional experiments aimed at elucidating the mechanisms of OVA-induced 60 
suppression, OVA-tolerized mice were sensitized with the LACK model antigen, challenged with 61 
LACK alone or LACK and OVA together, and LACK-specific T cells were visualized by flow 62 
cytometry. 63 
64 
Results: In both the ragweed and the LACK model, allergen-induced airway inflammation and 65 
AHR were strongly reduced in mice challenged with both the allergen and OVA compared to 66 
mice challenged with the allergen alone. OVA-induced protection did not result from competition 67 
between OVA and the allergen, was mediated by OVA-specific CD25
+
 Treg, required both68 
CTLA-4 and ICOS signaling, and was partially dependent on IL-10. Bystander suppression was 69 
associated with reduced proliferation of allergen-specific Th2 cells and decreased numbers of 70 
airway DC migrating to the lungs.  71 
72 
Conclusion: Our results demonstrate that Treg specific for a third-party drug antigen could 73 
control allergic immune responses and lung inflammation when re-stimulated in vivo.74 
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Clinical implications: This study paves the way for the development of a novel therapeutic 75 
strategy that could control allergen-specific Th2 responses in patients with allergic asthma. 76 
77 
Capsule summary: This study provides the proof of concept that bystander suppression 78 
mediated by Treg specific for a third-party drug antigen could be used as an efficient strategy to 79 
control allergen-specific Th2 cells and asthma symptoms in allergic individuals. 80 
81 
Key words: asthma, immune tolerance, airway inflammation, Th2, Treg, specific immunotherapy 82 
83 
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Abbreviations: Ag, antigen; APC, antigen-presenting cells; AHR, airway hyperresponsiveness; 84 
Alum, aluminium hydroxide; BAL, bronchoalveolar lavages; BALF, bronchoalveolar lavage 85 
fluids; BSA, bovine serum albumin; CFSE, carboxyfluorescence diacetate succinimidly ester; 86 
DCs, dendritic cells; ELISA, enzyme-Linked immunosorbent assay; FACS, fluorescence 87 
activated cell sorter; FITC, fluoresceinisothiocyanate; LACK, Leishmania homolog of receptors 88 
for activated c kinase antigen; LN, lymph nodes; Ig, immunoglobulin; IFN, interferon; IL, 89 
interleukin ; i.p., intraperitoneal ; i.n., intranasal; MCH, methacholine; MedLN, mediastinal LN; 90 
OVA, ovalbumin; PCR, polymerase chain reaction; PE, phycoerythrin; PBS, phosphate-buffered 91 
saline; PLN, popliteal LN; RNA, ribonucleic acid; SIT, specific immunotherapy; Teff, effector T 92 
cells; Tg, transgenic; Th, T helper ; Treg, regulatory T cells; WT, wild type 93 
94 
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Introduction 95 
Allergic diseases affect up to 30% of the population and their prevalence has steadily 96 
increased in recent decades probably due to numerous changes in the environment. Among 97 
allergic diseases, asthma is a chronic inflammation of the lungs caused by an inappropriate 98 
immune response to a single or multiple airborne allergens. This pathology has a substantial 99 
economic burden for which the only curative and specific method of treatment to this day is 100 
allergen-specific immunotherapy (SIT). SIT involves the administration by either subcutaneous 101 
injection or mucosal application of increasing doses of the allergen to which the patient is allergic 102 
to. Unfortunately, SIT is unsuitable for treating multi-sensitized patients, and some allergens are 103 
too immunogenic to be used in desensitization protocols. 104 
SIT induces a state of peripheral tolerance characterized mainly by the generation of 105 
allergen-specific Treg, suppressed effector cell proliferation and cytokine production against 106 
major allergens 
1, 2
. Indeed, IL-10 and/or TGF- producing Treg are the key factors for specific107 
immunotherapy in humans, considered as a model of tolerance induction 
3-5
. It has been shown108 
that treating naive (non-sensitized) mice with OVA aerosols leads to IgE-unresponsiveness to 109 
OVA 
6
, and induces the development of OVA-specific Treg which prevented the development of 110 
asthma upon subsequent sensitization and challenge with OVA 
7
. Moreover, lung draining lymph 111 
node (LN) dendritic cells (DC) first encountering an inhaled antigen transiently produced IL-10 
7
. 112 
These phenotypically mature DC induce the development of CD4
+
 Treg that also produce high 113 
amounts of IL-10 
8
. TGF--expressing Treg also play a role for tolerance induction to inhaled 114 
antigens 
5, 9
. Interestingly, it has been suggested that tolerance induced by SIT was not only 115 
limited to the administered allergen but also conferred protection against other allergens 
10, 11
.116 
This non-specific and beneficial action of SIT could be explained by the activation of bystander 117 
Treg. 118 
Bystander immunosuppression was first described by Bullock et al. as a process in which 119 
antigen (Ag)-specific Treg inhibit T effector cell responses directed to both the targeted Ag and to 120 
a co-localized third-party Ag 
12
. Due to the requirement that the tolerogen and the Ag have to be121 
physically linked, i.e. presented by the same antigen-presenting cell (APCs), in order for 122 
suppression to occur, the terms « linked suppression » or « linked recognition » were coined. In 123 
the field of oral tolerance, the term « bystander suppression » was introduced to describe an 124 
inhibition of a T cell memory response as a result of a regulatory response to an unrelated but 125 
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colocalized tolerogen 
13, 14
. In bystander suppression, the tolerogen and third-party Ag do not126 
need to be presented by the same APC. In this case, soluble mediators induce suppression of the 127 
response directed to the third-party Ag 
13, 15-17
.128 
In the present study, we have sought to investigate whether Treg specific for a third-party 129 
“drug” antigen could control allergic immune responses and lung inflammation in mice. To this 130 
aim, mice were tolerized to OVA, sensitized to ragweed, and eventually challenged with aerosols 131 
of ragweed alone or ragweed and OVA together. 132 
133 
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Results 134 
135 
Exposure to OVA aerosols inhibits ragweed- and LACK-induced allergic asthma in OVA-136 
tolerized mice 137 
To determine whether Treg specific for a third-party antigen could control allergic airway 138 
inflammation in mice, mice were tolerized to OVA through intranasal administrations, sensitized 139 
to ragweed and further exposed to aerosols of ragweed alone or ragweed and OVA together (Fig 140 
1, A). When compared to the group challenged with ragweed only, mice exposed to both ragweed 141 
and OVA showed decreased AHR (Fig 1, B) and reduced numbers of total cells, eosinophils and 142 
lymphocytes in broncho alveolar lavage fluids (BALF) (Fig 1, C). We further analyzed airway-143 
infiltrating T cells for expression of the Th2- marker, T1/ST2 (IL-33Ra). Compared to the mice 144 
challenged with ragweed alone, the number of T1/ST2
+
 CD4
+
 T cells was reduced in the BALF145 
of mice challenged with ragweed and OVA aerosols (Fig 1, D). The amounts of IL-5 and IL-13 146 
in the lungs were also reduced upon challenge with ragweed and OVA while IFN- levels 147 
remained low and similar in both groups (Fig 1, E). This phenomenon was not observed in mice 148 
than have not been tolerized to OVA prior to ragweed sensitization (Supplementary Figure 1) 149 
further supporting a role for OVA-specific Treg in this phenomenon and ruling out the possibility 150 
that it could result from competition between OVA and ragweed for antigen presentation. 151 
To generalize our findings and to further dissect the mechanisms involved, we switched to 152 
another experimental model in which BALB/c mice were sensitized to the model antigen LACK, 153 
tolerized to OVA through intranasal administration, and further exposed to aerosols of LACK 154 
alone, or LACK and OVA (Fig 2, A). As observed with ragweed, mice exposed to both 155 
LACK/OVA showed decreased AHR (Fig 2, B), and reduced total numbers of cells, eosinophils 156 
and lymphocytes in BALF (Fig 2, C). Compared to control mice challenged with LACK alone, 157 
both the frequency and the number of T1/ST2
+
 CD4
+
 T cells were reduced in the BALF of mice158 
challenged with LACK/OVA aerosols (Fig 2, D). The amounts of IL-4, and IL-13 in the BALF 159 
were also reduced upon challenge with LACK/OVA aerosols while IFN- levels remained low 160 
and similar in both groups (Fig 2, E). The lungs of LACK/OVA-challenged mice contained less 161 
IL-4-, and IL-5- secreting CD4
+
 T cells than those challenged with LACK only as demonstrated162 
by intracellular cytokine staining of lung cells upon LACK restimulation (Fig 2, F). In contrast, 163 
the amounts of LACK-specific -IgE and -IgG1 were not affected by additional OVA exposure 164 
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(Fig 2, G). Altogether, our results suggested that exposure to OVA aerosols could inhibit allergic 165 
airway inflammation and allergen-specific Th2 immune responses in mice that have been 166 
tolerized with OVA prior to sensitization and challenge with either ragweed or LACK. 167 
168 
The inhibition of LACK-induced airway inflammation in OVA-tolerized mice is mediated 169 
by OVA-specific CD25
+
 Treg 170 
Previous experiments have shown that the intranasal administration of OVA to BALB/c mice 171 
induces OVA-specific Treg that express CD25. To investigate whether these cells were 172 
responsible for the inhibition of LACK-induced airway inflammation in OVA-tolerized LACK-173 
sensitized mice, CD4
+
 T cells were purified from the spleen of mice that have been previously174 
tolerized to OVA or bovine serum albumine (BSA), or treated with PBS. Cells were injected into 175 
LACK-sensitized recipients that were further challenged with both LACK and OVA (Fig 3, A). 176 
Compared to mice injected with CD4
+
 T cells purified from BSA-tolerized or PBS-treated177 
donors, mice injected with CD4
+
 T cells from OVA-tolerized mice exhibited decreased AHR178 
(Fig 3, B), reduced numbers of total cells, eosinophils and lymphocytes (Fig 3, C) and T1/ST2
+
179 
CD4
+ 
T cells in BALF (Fig 3, D), and reduced numbers of IL-4 and IL-5-secreting CD4
+
 T cells180 
in lungs (Fig 3, E). In striking contrast, no inhibition of LACK-induced airway inflammation or 181 
LACK-specific Th2 immune responses were observed when CD4
+
 T cells from OVA-tolerized182 
mice depleted of CD25
+
 cells prior to injection into LACK-sensitized mice. Lastly, both airway183 
inflammation and LACK-specific Th2 immune responses were inhibited when recipient mice 184 
were injected with CD25
+
 CD4
+
 T cells purified from the spleen of OVA-tolerized mice (Fig 3,185 
F-I). Therefore, the inhibition of LACK-induced airway inflammation that was observed in 186 
OVA-tolerized mice upon challenge with OVA relied on the activation of OVA-specific CD25
+
187 
Treg. 188 
189 
CTLA-4, ICOS, and IL-10 dependency of OVA-specific Treg in the control of LACK-190 
induced asthma 191 
Treg mediate suppression through various mechanisms including the secretion of inhibitory 192 
cytokines such as IL-10, the induction of cytolysis, metabolic disruption and the inhibition of 193 
antigen presentation by dendritic cells (DCs) through a CTLA-4-dependent mechanism 
18
. 194 
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Furthermore, it was recently shown that ICOS mediated the generation and function of CD25
+ 
195 
CD4
+ 
FoxP3
+ 
Treg conveying respiratory tolerance 
19
, and that ICOS expression defined a subset196 
of IL-10 secreting Treg 
20
 and was required for the production of IL-10 by these cells 
21
. 197 
Therefore, we sought to elucidate the role of CTLA-4, ICOS and IL-10 in the inhibition of 198 
LACK-induced airway inflammation induced by OVA aerosols. To this aim, LACK-sensitized 199 
OVA-tolerized mice were challenged with both LACK and OVA and treated or not with blocking 200 
mAbs directed to CTLA-4, ICOS or IL-10R (Fig 4, A). CTLA-4 blockade prevented the 201 
inhibition of AHR induced by OVA aerosols, as well as the reduction in the number of total cells, 202 
eosinophils, lymphocytes and T1/ST2
+
 Th2 cells in BALF, and IL-4- and IL-5-producing LACK-203 
specific CD4
+
 in lungs (Fig 4, B-D). Likewise, blocking ICOS/ICOSL interactions abolished the204 
protection that was induced by OVA aerosols in OVA-tolerized LACK-sensitized mice but did 205 
not have any detectable effect in mice that have not been tolerized to OVA (Fig 4, F, G). In 206 
contrast to anti-CTLA-4 and anti-ICOS mAbs that restored both AHR and allergic airway 207 
inflammation in OVA-tolerized mice exposed to OVA, anti-IL-10R mAbs restored AHR but not 208 
allergic airway inflammation (Fig 4, F, G). Therefore, the inhibition of AHR and airway 209 
inflammation that was induced by OVA aerosols in OVA-tolerized mice upon sensitization and 210 
challenge with LACK was dependent on both CTLA-4, ICOS and partially on IL-10. 211 
212 
OVA-specific Treg inhibited the proliferation of LACK-specific Th2 cells and the subsequent 213 
airway inflammation 214 
To further dissect the molecular mechanisms by which OVA-specific Treg inhibited LACK-215 
induced allergic asthma, CD4
+
 T cells from Thy1.1
+
 LACK-specific WT15 TCR transgenic mice216 
were differentiated in vitro under Th2 polarizing conditions, labeled with CFSE, and injected into 217 
OVA- or BSA- tolerized recipients before being challenged with LACK/OVA (Fig 5, A). As 218 
compared to BSA-tolerized mice, OVA-tolerized animals injected with LACK-specific Th2 cells 219 
exhibited decreased AHR (Fig 5, B), and reduced numbers of eosinophils and lymphocytes in the 220 
BALF (Fig 5, C). In addition, both the frequency and the number of donor Th2 cells were 221 
reduced in the BALF, lung and MLN, but not in the blood of OVA-tolerized mice compared to 222 
BSA-tolerized mice (Fig 5, D). Furthermore, LACK-specific Th2 cells had undergone more 223 
divisions in BSA-tolerized mice than in OVA-tolerized mice (Fig 5, E) further suggesting that 224 
OVA aerosols inhibited the proliferation of LACK-specific Th2 cells possibly at the level of 225 
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antigen presentation. To directly test this latter hypothesis, LACK-specific Th2 cells were 226 
injected into either OVA- or BSA-tolerized mice, and further challenged with both LACK and 227 
OVA. Cells were then purified from the mediastinal LN (MedLN) and distal popliteal LN (PLN) 228 
and incubated with CFSE-labeled LACK-specific WT15 CD4
+
 T cells to assess their ability to229 
induce proliferation. As expected, PLN cells did not induce T cell proliferation (Fig 5, F).. 230 
Furthermore, LACK-specific T cells proliferated more vigorously when incubated with MedLN 231 
cells from BSA-tolerized mice than when incubated with MedLN cells from OVA-tolerized mice 232 
(Fig 5, F). To investigate whether this phenomenon resulted from quantitative (i.e. different 233 
number of LACK-loaded DCs in OVA-tolerized and BSA-tolerized mice) or qualitative 234 
differences (i.e. similar number of LACK-loaded DCs in OVA-tolerized and BSA-tolerized mice 235 
but different ability to induce T cell proliferation), we administered FITC-labeled latex beads to 236 
OVA- and BSA-tolerized mice at the time of the challenge with LACK and OVA, and we 237 
measure the frequency of bead
+
 DCs in MedLN 16 hrs later. While bead
+
 DCs were readily238 
detected in the MedLN of both OVA- and BSA-tolerized mice and expressed similar surface 239 
levels of CD80, CD86, OX40L and MHC class II molecules (not shown), the frequency of bead
+
240 
DCs was decreased from 4.7 ± 0.7 % in BSA-tolerized mice to 1.4 ± 0.3 % in OVA-tolerized 241 
animals (Fig 5, H). Altogether, our data suggested that OVA-specific Treg inhibited the 242 
proliferation of LACK-specific Th2 cells by preventing the migration of airway DCs to MedLN. 243 
244 
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Discussion 245 
In his paper, we have demonstrated that OVA-specific Treg could inhibit allergic airway 246 
inflammation induced by sensitization and challenge with ragweed. OVA-specific Treg were also 247 
efficient to protect mice from allergic airway inflammation induced by the immunodominant 248 
LACK antigen further validating our finding to second allergen. In addition, BSA-tolerized mice 249 
were protected from LACK-induced allergic asthma when challenged with both LACK and BSA 250 
further suggesting that the phenomenon that we have observed was not restricted to OVA-251 
specific Treg (data not shown). Interestingly, the phenomenon that we have described in this paper 252 
may explain the protective effects of SIT against unrelated allergens other than the one primarily 253 
targeted as reported in several epidemiological studies 
10, 11, 22
.254 
In the LACK model, we have found that the number of allergen-specific Th2 cells in 255 
BALF, the frequency and number of IL-4 and IL-5 producing CD4
+
 T cells as well as the IL-4,256 
IL-5, and IL-13 amounts in lungs were decreased in mice challenged with both LACK and OVA 257 
compared to mice challenged with LACK alone. OVA-induced protection did not result from a 258 
competition between OVA and LACK for antigen presentation because it was only observed in 259 
mice that have been previously tolerized with OVA. In contrast, experiments in which CD4
+
 T260 
cells were purified from the spleen of PBS-treated, BSA- or OVA-tolerized mice and injected 261 
into LACK-sensitized recipient mice showed that protection was antigen-specific and mediated 262 
by Treg. 263 
Further experiments showed that CTLA-4 was absolutely required for OVA-induced 264 
suppression of LACK-mediated asthma. While we did not elucidate the mechanisms by which 265 
CTLA-4 acted, CTLA-4 was shown to be essential for the function of naturally occurring Treg 266 
which constitutively express this molecule. Indeed, CTLA-4 deficiency in Treg impaired both 267 
their in vivo and in vitro suppressive function. In addition, CTLA-4 prevented CD28 signaling in 268 
effector T cells (Teff) by competing with CD80 and CD86, and/or induced the synthesis of the 269 
tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) by the APCs leading to T-270 
cell suppression by both local depletion of tryptophan and induction of apoptosis via tryptophan 271 
catabolites 
23
. While we were unable to detect increased death of LACK-specific T cells in OVA-272 
tolerized mice challenged with both OVA and LACK (not shown), we cannot rule out the 273 
possibility that this phenomenon was partially responsible for OVA-induced protection.  274 
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Blocking ICOS-ICOSL interactions resulted in the same effect as CTLA-4 inhibition, a 275 
result in agreement with a previous study showing that ICOS
-/-
 Treg did not confer protection upon 276 
transfer to asthmatic mice demonstrating a crucial role of ICOS in their suppressive function 
19
. 277 
As ICOS was shown to define a subset of IL-10-producing Treg, we next investigated whether 278 
OVA-induced suppression of the disease required IL-10. IL-10R blockade prevented OVA-279 
induced suppression of AHR, but did not affect LACK-induced inflammation in our model. It 280 
remains to be determined whether IL-10 is produced by the CD25
+
Treg or by other cells as 281 
previously described Kearley et al. 
24
. Taken together, these data underline the multiple and 282 
complex effects of CD25
+
 Treg. While these cells have been proposed to act via cell contact-283 
dependent mechanisms in vitro, these cells have been proposed to work through various 284 
mechanisms including inhibitory cytokines and non-cytokine-dependent mechanisms in vivo, 285 
depending on the experimental conditions 
25
. Our findings also suggest that inflammation and286 
AHR can be uncoupled and are in agreement with previous studies that demonstrate that effects 287 
on inflammation are not always predictive of AHR changes 
26-29
. Indeed, this might also hold true288 
in human asthma, in which anti-IL-5 mAb treatment reduced blood and lung eosinophilia but did 289 
not affect lung function 
30
.290 
Adoptive transfer of CFSE-labeled LACK-specific Th2 cells into OVA-tolerized recipient 291 
mice demonstrated that OVA-specific Treg significantly reduced the number of LACK-specific 292 
Th2 cells in the BALF, lung and MLN by affecting their proliferation. Imaging data in mice have 293 
showed that Treg do not directly interact with Teff but rather with DC, altering the latter and 294 
diminishing subsequent DC-Teff cells conjugate formation in vivo 
31, 32
 a phenomenon that could295 
explain our results. In addition, Derks and colleagues have envisioned two hypotheses of APC 296 
function in bystander suppression 
33
: a passive APC model, in which the APCs would present297 
MHC-peptide to the Treg, stimulating them to produce immunosuppressive cytokines that would 298 
further binds their cognate receptors on the third-party Teff, or an active APC model, in which the 299 
APCs would propagate regulatory effects from the Treg to the Teff through various APC products. 300 
These two hypotheses remain to be tested in our model.  301 
Our results demonstrate that Treg specific for a third-party drug antigen could control 302 
allergic immune responses and lung inflammation when re-stimulated in vivo. This study paves 303 
the way for the development of a novel therapeutic strategy that could control allergen-specific 304 
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Th2 responses in patients with allergic asthma, and more specifically in patients who are 305 
sensitized to multiple allergens. 306 
307 
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FIGURE LEGENDS 308 
Figure 1. AHR, airway inflammation and cytokine levels in ragweed-sensitized, OVA-309 
tolerized mice upon ragweed challenge. (A) Experimental protocol. Mice were treated with 310 
three i.n. injections of OVA, and four i.n. injections of ragweed. Mice were then either 311 
challenged with ragweed or ragweed/OVA, and analyzed one and two days after the last i.n. 312 
injection. (B) AHR. Whole body plethysmography in mice exposed to ragweed (filled squares), 313 
ragweed/OVA (empty circles), or PBS (crosses). (C) Number and phenotype of BALF cells. 314 
BALF cells were analyzed by FACS in mice exposed to ragweed only (black bars), to both 315 
ragweed and OVA aerosols (empty bars) or to PBS (grey bars). Eosinophils, E; neutrophils, N; 316 
lymphocytes, L; macrophages, M. (D) Frequency and number of Th2 cells in the airways. BALF 317 
cells were stained with CD4 and T1/ST2 mAbs and analyzed by FACS. (E) Cytokine levels in 318 
lung cells. IL-4, IL-5 and IFN- levels were assessed by ELISA after in vitro stimulation with 319 
LACK protein (0.1mg/ml), anti-CD28 (1g/ml) and brefeldin A (5g/ml). Data are expressed as 320 
mean  s.e.m. of 2 experiments with n=8 mice per group. n.s., non significant; * P<0.05; ** 321 
P<0.01. 322 
Figure 2. AHR, airway inflammation and cytokine levels in OVA-tolerized mice exposed to 323 
both OVA and LACK aerosols. (A) Experimental protocol. Mice were sensitized with two 324 
intra-peritoneal injections of LACK in Alum, treated with three i.n. injections of OVA, and 325 
challenged daily for 5 days with LACK aerosols or LACK/OVA aerosols. Mice were analyzed 326 
one and two days after the last aerosol. (B) AHR. Whole body plethysmography (right), and 327 
dynamic lung resistance and compliance (left) were monitored in mice exposed to LACK 328 
aerosols (filled squares), LACK/OVA aerosols (empty circles) or PBS (crosses, dashed line). (C) 329 
Number and phenotype of BALF cells. BALF cells were counted and analyzed by FACS in mice 330 
exposed to PBS (dashed bars), LACK (black bars) or LACK/OVA aerosols (empty bars). Data 331 
show the number of eosinophils (E), neutrophils (N), lymphocytes (L), macrophages (M). (D) 332 
Frequency and number of Th2 cells in the airways. BALF cells were stained with anti-CD4, CD3 333 
and T1/ST2 mAbs and analyzed by FACS. Data show representative FACS profiles, numbers 334 
indicate the mean frequency  s.e.m and histograms show the absolute numbers of T1ST2+ CD4+335 
T cells for the indicated groups. (E) Cytokine levels in BALF. Mice were analyzed for IL-4, IL-5, 336 
IL-13 and IFN- by cytometric bead array (CBA). (F) Cytokine secretion by lung CD4+ T cells.337 
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IL-4, and IL-5-secreting CD4
+
 T cells were assessed by FACS after in vitro stimulation with338 
LACK protein (0.1mg/ml), anti-CD28 (1g/ml) and brefeldin A (5g/ml). Data show 339 
representative FACS profiles, numbers indicate the mean frequency  s.e.m and histograms show 340 
the absolute numbers for the indicated groups. (G) Immunoglobulins. Levels of serum LACK-341 
specific -IgE and -IgG1 were assessed in mice upon challenge with LACK or LACK/OVA 342 
aerosols. All data show either individual mice with bar indicating the mean, with n = 6 mice per 343 
group pooled from four different experiments. n.s., non significant, * P<0.05, ** P<0.01, *** 344 
P<0.0001. 345 
Figure 3. AHR, airway inflammation and cytokine levels in mice injected with CD4
+
 T cells346 
from OVA-tolerized mice. (A) Experimental protocol. Mice were sensitized with two i.p. 347 
injections of LACK in Alum, and injected 9 d later with 4 X 10
6
 CD4
+
 T cells (A-E), or 4 X 10
6
348 
CD25
-
CD4
+
 T cells (F-I) or 1.5 X 10
6
 CD25
+
CD4
+
 T cells (F-I) prepared from the spleen of mice349 
exposed to OVA, BSA, or PBS. Sensitized mice were then challenged with LACK/OVA aerosols 350 
for five days and analyzed one and two days after the last aerosol. (B, F) AHR. Whole body 351 
plethysmography was monitored in the indicated mice challenged to LACK/OVA aerosols in 352 
response to increased doses of inhaled methacholine. Control mice (vehicle) were sensitized with 353 
LACK, non-transferred and challenged with PBS. (C, G) Number and phenotype of BALF cells. 354 
BALF cells were analyzed by FACS for the number of eosinophils (E), neutrophils (N), 355 
lymphocytes (L), macrophages (M). (D, H) Frequency and number of Th2 cells in the airways. 356 
BALF cells were stained with anti-CD3, -CD4 and T1/ST2 mAbs and analyzed by FACS. (E, I) 357 
Cytokine secretion by lung CD4
+
 T cells. IL-4, and IL-5-secreting CD4
+
 T cells were assessed by358 
FACS after in vitro stimulation with LACK protein (0.1mg/ml), anti-CD28 (1g/ml) and 359 
brefeldin A (5g/ml). Data show numbers of IL-4 and IL-5-secreting CD4+ T cells in lungs. All360 
data show either individual mice or are expressed as mean  s.e.m, with n = 5 mice per group 361 
pooled from two experiments. P values have been calculated by comparing OVA-tolerized mice 362 
to BSA-tolerized mice, ns, non significant, * P<0.05, ** P<0.01, *** P<0.0001. 363 
364 
Figure 4: AHR and airway inflammation in mice treated with anti-CTLA-4, anti-IL-10R, or 365 
anti-ICOS. (A) Experimental protocol. Mice were sensitized with two i.p. injections of LACK in 366 
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Alum, treated with three i.n. injections of OVA, treated or not with anti- CTLA-4 mAb, -IL-10R, 367 
-ICOS, or IgG1 isotype mAb at the indicated time, and challenged daily for 5 days with LACK or 368 
LACK/OVA aerosols. Mice were analyzed one and two days after the last aerosol. (B) and (F) 369 
AHR. Whole body plethysmography in response to increasing doses of inhaled methacholine in 370 
the indicated groups of mice. (C) and (G) Number and phenotype of BALF cells. BALF cells 371 
were analyzed by FACS in the indicated groups of mice. Eosinophils, E; neutrophils, N; 372 
lymphocytes, L; macrophages, M. (D). Number of Th2 cells in the airways. BALF cells were 373 
stained with anti -CD3, -CD4 and T1/ST2 mAbs and analyzed by FACS. (E). IL-4, and IL-5-374 
secreting CD4
+
 T cells were assessed by FACS after in vitro stimulation with LACK protein375 
(0.1mg/ml), anti-CD28 (1g/ml) and brefeldin A (5g/ml). Data are expressed as mean  s.e.m 376 
of 3 experiments with n=6 mice per group. n.s., non significant; * P<0.05; ** P<0.01; *** 377 
P<0.0001. 378 
Figure 5. AHR, airway inflammation, cytokine levels and T cell proliferation in OVA-379 
tolerized mice injected with LACK-specific Th2 cells and exposed to LACK/OVA. (A) 380 
Experimental protocol. Mice were treated with three i.n. injections of OVA or BSA, injected with 381 
1.5 X 10
6
 CFSE-labeled Thy1.1
+
 LACK-specific Th2 cells. Mice were injected intranasally 2 d382 
later with LACK/OVA and analyzed 4 and 5 days later. (B) AHR. Whole body plethysmography 383 
was monitored in mice tolerized to OVA (empty circles) or BSA (filled squares, and crosses) and 384 
exposed to aerosols of LACK/OVA (full lines) or to PBS (dashed lines). Data are expressed as 385 
mean  s.e.m. (C) Number and phenotype of BALF cells. BALF cells were analyzed by FACS in 386 
the indicated groups of mice. Eosinophils, E; neutrophils, N; lymphocytes, L; macrophages, M. 387 
Data are expressed as mean  SEM of 3 experiments with n=6-8 mice per group. (D) Numbers of 388 
Thy1.1
+
 LACK-specific Th2 cells in BALF, lung, and medLN and frequency in the blood of389 
BSA- (filled bars) or OVA- (empty bars) tolerized mice challenged with LACK/OVA aerosols. 390 
(E) Representative plots of CFSE (left panels) and MFI of CFSE (right panels) of the indicated 391 
mice. (F) In vitro antigen presentation assay. Whole cell suspensions prepared from the MedLN 392 
and PLN of OVA- or BSA-exposed mice were incubated for 3 days with CFSE-labeled LACK-393 
specific Th2 cells. Data show representative CFSE plots for the indicated mice with the 394 
frequency of divided cells as mean  s.e.m of 2 experiments with n=6 mice per group. (G) Mice 395 
underwent the same protocol as shown in panel A, but also received fluorescent latex beads 396 
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during LACK/OVA challenge. Beads
+
CD11c
+
 migratory DCs were analyzed by FACS in the397 
MedLN of BSA- (filled bars) or OVA- (empty bars) tolerized mice challenged with LACK/OVA 398 
aerosols. n.s., non significant; * P<0.05; ** P<0.01; *** P<0.0001. 399 
400 
Supplementary Figure 1. AHR and airway inflammation in LACK-sensitized mice 401 
challenged with LACK alone or LACK and OVA aerosols. (A) Experimental protocol. Mice 402 
were sensitized with two i.p. injections of LACK in Alum, and challenged daily for 5 days with 403 
LACK or LACK/OVA aerosols, or PBS. Mice were analyzed one and two days after the last 404 
aerosol. (B) AHR. Whole body plethysmography in mice exposed to aerosols of LACK (filled 405 
squares), LACK/OVA (empty circles) or PBS (crosses). (C) Number and phenotype of BALF 406 
cells. BALF cells were analyzed by FACS in mice exposed to LACK only (black bars), to both 407 
LACK and OVA aerosols (empty bars) or to PBS (grey bars). Eosinophils, E; neutrophils, N; 408 
lymphocytes, L; macrophages, M. Data are expressed as mean  s.e.m. of 2 experiments with 409 
n=8 mice per group. n.s., non significant. 410 
411 
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METHODS 412 
413 
Mice. 6-week old BALB/c mice were purchased from The Centre d’Elevage Janvier (France) and 414 
housed under SPF conditions. LACK TCR transgenic mice (WT15 RAG-1 KO) on the BALB/c 415 
background as previously described 
34
 were bred in our animal facility at the Institut de 416 
Pharmacologie Moleculaire et Cellulaire (Valbonne, France). In this study, WT15 transgenic 417 
mice were further crossed onto RAG-1
-/-
 Thy1.1
+/+ 
BALB/c mice. All experimental protocols418 
were approved by the local animal ethic committee.  419 
Reagents. LACK recombinant protein was produced in E. coli, purified as described 
35
, and420 
detoxified using an Endotrap column (Profos). Lipopolysaccharide contents in LACK protein 421 
were below 5 ng/mg as determined using Limulus Amoebocyte Lysate (LAL) assay (Pierce). 422 
LACK156-173 peptide was purchased from Mimotopes. T1/ST2 mAbs were purchased from MD 423 
Biosciences. Monoclonal antibodies to CD3, CD4, CD25, Thy1.1, CD11c, IA/IE, CD80, CD86, 424 
IL-4 and IL-5 were purchased from BD Biosciences.    425 
Induction of allergic asthma and tolerization to OVA. Sensitization was performed by 2 426 
intraperitojneal (i.p.) injections of 10 µg of LACK in 2 mg of Aluminium hydroxide (Alum) 427 
(Pierce) at day 0 and 7. On days 12, 13 and 14, mice were tolerized to OVA by injecting i.n. 100 428 
g of LPS-free OVA (Profos) as described 7. From day 23 to day 27, mice were either exposed to429 
LACK (0.15%) or to LACK plus OVA (0.2%) aerosols (administered 8 hour apart) for 20 min 430 
using an ultrasonic nebulizer (Ultramed, Medicalia). Mice were analyzed on day 28 and 29 for 431 
AHR and airway inflammation, respectively. When indicated, mice were injected with either 0.5 432 
mg of anti-CTLA-4 mAb (9H10), anti-ICOS (17G9), or anti-IL-10R (1B1.3A) every other day 433 
over the challenge period starting one day before the first aerosol. For ragweed-induced asthma, 434 
mice were first tolerized to OVA by receiving i.n. injections of OVA on days 0, 1, and 2 and 435 
further sensitized to ragweed via i.n. administrations of 25 µg ragweed (Greer laboratories) on 436 
days 11, 15, 19, and 23. Mice received a last challenge of ragweed on day 27 or ragweed and 437 
OVA on days 26 and 27. Mice were analyzed on day 28 for AHR and on day 29 for airway 438 
inflammation.  439 
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Th2 cell transfers. In some experiments, mice were first tolerized to OVA, BSA or PBS and 440 
injected i.v on day 11 with LACK-specific CD4+ Th2 cells. Mice were challenged 24 hours later 441 
with a single i.n. injection of LACK (30 g) and OVA (100 g), and assessed for AHR, and 442 
immunological parameters 3 and 4 days later, respectively. 443 
AHR. For non-invasive measurements, mice were analyzed one day after the last aerosol 444 
challenge using whole body plethysmography as described 
36
. Invasive measurements of dynamic445 
lung resistance and compliance were performed one day after the last aerosol challenge using a 446 
Flexivent apparatus (SCIREQ, Emka Technologies) as previously described 
37
. Briefly, mice 447 
were anesthetized (5 ml/kg Dormitor 10 % (Medetomidine, Pfizer) - Imalgene 10% (Ketamine, 448 
Merial) tracheotomized, paralyzed (5 ml/kg Pavulon 1% (Pancuronium bromide, Organon) and 449 
immediately intubated with an 18-G catheter, followed by mechanical ventilation. Respiratory 450 
frequency was set at 150 breaths/min with a tidal volume of 0.2 ml, and a positive-end expiratory 451 
pressure of 2 ml H2O was applied. Increasing concentrations of methacholine (0-24 mg/ml) were 452 
administered at the rate of 20 puffs per 10 seconds, with each puff of aerosol delivery lasting 10 453 
ms, via a nebulizer aerosol system with a 2.5-4 m aerosol particle size generated by a nebulizer 454 
head (Aeroneb, Aerogen). Baseline resistance was restored before administering the subsequent 455 
doses of methacholine. 456 
Analysis of BALF cells. Mice were bled and a canula was inserted into the trachea. Lungs were 457 
washed 3 times with 1 ml of warmed PBS. For differential BALF cell counts, cells were stained 458 
with mAb anti-CCR3 (R&D), anti-Gr1, anti-CD3 and anti-CD19 mAbs  (Becton Dickinson, BD) 459 
and analyzed by FACS using a FACScalibur flow cytometer and Cellquest software. Eosinophils 460 
were defined as CCR3
+
 CD3
-
CD19
-
, neutrophils as Gr-1
high
 CD3
-
CD19
-
, lymphocytes as461 
CD3
+
CD19
+
 and alveolar macrophages as large autofluorescent cells.462 
Serum antibody measurements. Serum LACK-specific IgG1 and IgE were measured by 463 
ELISA. For IgG1 quantification, antigen-coated Maxisorp plates (Nunc) were incubated with 464 
serial dilution of sera and biotinylated anti-IgG1 mAb (BD). For antigen-specific IgE, plates were 465 
first coated with the respective capture mAb (BD), and incubated with serum dilutions. 466 
Biotinylated-LACK antigen was then added. HRP-conjugated streptavidin (BD) and TMB (KPL) 467 
were used for detection.   468 
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Tissue processing. Lungs, LN or spleens were cut to small pieces in HBSS containing 400 U 469 
type I collagenase and 1 mg/ml DNAse I and digested for 30 min at 37°C. Cells were strained 470 
through a 70 m cell strainer. Erythrocytes were lysed with ACK lysis buffer.  471 
Cytokine assays. Lung samples were homogenized in C
2+
 and Mg
2+
 free HBSS. BAL and lung472 
supernatants were used. Multiplex IL-4, IL-5, IL-13 and IFN- analysis were performed with 473 
CBA using FACS array (BD Bisociences). For intracellular staining, cells were incubated with 474 
100 µg/ml LACK and 1 µg/ml of anti-CD28 (BD) for 6 h. Brefeldin A (5 µg/ml, Sigma) was 475 
added during the last 4 h. Cells were then stained with anti-CD4 mAb, fixed, permeabilized using 476 
cytofix/cytoperm reagent (BD), stained with anti-IL-4, or IL-5 (BD) and analyzed by FACS.  477 
CD4
+
 T cell transfer.  Donor mice were tolerized to OVA, BSA or PBS as described above. 478 
Cells were prepared from spleens 21 days later, and CD4
+
 T cells were enriched by negative479 
depletion using CD4 isolation kit (Dynal) and further sorted using a high-speed sorter 480 
VANTAGE SETLO
+
flow cytometer (BD) after staining with anti-CD3 and anti-CD4 mAbs. 481 
CD4 purity was > 95%. In some experiments, enriched CD4
+
 T cells were stained with antibodies 482 
to CD25, CD4 and CD3, and CD25
-
 and CD25
+
 CD4
+
 T cell populations were sorted by FACS. 483 
Sorted cells were then injected i.v. into sensitized mice (4 X 10
6
 or 1.5 X 10
6
 cells per mouse, 484 
respectively). 485 
Statistic analysis. ANOVA for repeated measures was used to determine the levels of difference 486 
between groups of mice for plethysmography measurements. Comparisons for all pairs were 487 
performed by Mann-Whitney U test. Significance levels were set at a P value of 0.05.  488 
489 
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